DaltonTx, a UK-based technology company, has exited stealth mode and completed a £4 million seed financing round to develop adaptive, AI-enabled discovery platforms for drug development. The company’s platform integrates into existing pharma, biotech, and CRO workflows, supporting both small molecules and biologics.

DaltonTx was co-founded by Dr Garry Pairaudeau, Adrian Rossall, Dr Anthony Bradley, and Professor Charlotte Deane MBE, combining expertise in drug discovery, machine learning, software engineering, and structural bioinformatics. The team has previously built AI discovery platforms at AstraZeneca and Exscientia, and brings academic research from the University of Oxford.

Dr Garry Pairaudeau, co-founder of DaltonTx, said: “AI offers an opportunity to transform drug discovery, but it is still incredibly challenging for organisations to build their own capabilities. DaltonTx exists to change that. We are solving high-impact challenges with adaptive AI-enabled systems that integrate into scientific workflows, evolve with every experiment, and give organisations lasting AI capability.”

Professor Charlotte Deane MBE added: “By combining cutting-edge machine learning with deep drug discovery expertise, we are creating technology that learns with every experiment and helps scientists turn ideas into impact.”

DaltonTx’s platform is designed to support complex R&D pipelines, enabling scientists to interact with AI models and combine human insight with machine learning. The seed financing was led by redalpine, IQ Capital Partners, and Seedcamp, with support from Oxford University Innovation.

Marc Moesser, investment manager at redalpine, said: “DaltonTx is poised to become the intelligence backbone of drug discovery, providing scientific reasoning capabilities and deep integration into real drug discovery workflows. Led by a highly impressive team of industry experts, we believe the DaltonTx platform will soon be indispensable for every R&D organization across pharma, biotech, and CROs.”

Mason Sinclair, principal at IQ Capital, added: “We are excited to back DaltonTx, a company poised to set a new standard in R&D execution.” Tom Wilson, partner at Seedcamp, said: “Their unique combination of drug discovery, machine learning, and software engineering expertise positions them to lead the next generation of AI in pharma.”